¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2023 Spring Semi-Annual Meeting 2ÀÏÂ÷ : 2023-05-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2023 Spring Semi-Annual Meeting 2ÀÏÂ÷ : 2023-05-20
±³À°ÀÏÀÚ : 2023-05-20
±³À°Àå¼Ò : ¿©¼ö¾×½ºÆ÷ÄÁº¥¼Ç

±³À°ÁÖÁ¦ : KGOG 2023 Spring Semi-Annual Meeting 2ÀÏÂ÷

ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸

´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-5420

À̸ÞÀÏ : kiskgog@hanmail.net

±³À°Á¾·ù : »êºÎÀΰú

Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : Àü¶ó³²µµ
±³À°½Ã°£ : 5 ½Ã°£ 53ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 09:00~09:02 Not-finished DDT studies-CIEL / VI-SEALER / CIRCUS status check ±è±âµ¿(ºÐ´ç¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 09:02~09:30 Not-finished DDT studies-GYANT preliminary analysis-Adnexal surgery, Myomectymy, Hysterectomy, Cancedr surgery ±è±âµ¿(ºÐ´ç¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 09:30~09:40 New study concepts - Completion local therapy after chemotherapy in metastatic cervical cancer ÀÌ»óÈÆ(¿ï»ê´ëº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 09:40~09:50 Common Database Model - Evidnet demonstration ±è±âµ¿(ºÐ´ç¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 10:00~10:15 The longest follow up for PARP inhibitor in newly diagnosed advanced ovarian cancer È«ÁøÈ­(°í·ÁÀÇ´ë)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 10:15~10:30 Latest update on PARPi indication label and therapeutic options in patients with recurrent ovarian cancer ÃÖ¹Îö(ºÐ´çÂ÷º´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 10:30~10:45 AZ current and future oncology pipeline ÀÓÀçÀ±(AZ, Medical Director)

Åä·Ð 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 10:45~10:55 discussion ()

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 11:00~11:03 Introduction/Review of on-going studies ÃÖÇöÁø(Á߾Ӵ뱤¸íº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 11:03~11:08 2-1. KGOG 3033 Surgery alone and surveillance in FIGO stage I malignant ovarian germ cell tumor ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 11:08~11:13 2-2. KGOG 3049 Phase II trial evaluating the Efficacy and safety of physician chosen chemotherapy with hormonaL therapy in patientS with heavily pretreated Advanced epithelial ovarian, fallopian tube or primary peritoneal cancer: A multicenter pilot study (ELSA) À̹æÇö(ÀÎÇϴ뺴¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 11:13~11:18 2-3. KGOG 3050 Laparoscopic vs laparotomic surgery in OV CA ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 11:18~11:23 2-4. KGOG 3053/NRG CC-008 clinical trial: A Non-Randomized Prospective Clinical Trail Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROC) ÃÖÇöÁø(Á߾Ӵ뱤¸íº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 11:23~11:28 2-5. KGOG3055/JGOG3024 Biobank cohort study in subjects who have not developed ovarian cancer to determine BRCA1/2 gene variants and the incidence, clinicopathological characteristics, and risk factors in the development of cancer ÀÌÁ¤¿ø(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 11:28~11:33 2-6. KGOG 3058 Effectiveness and safety of PARP-inhibitor maintenance therapy in recurrent ovarian cancer patients in real world; Retrospective cohort study (ESPOIR) ÃÖÇöÁø(Á߾Ӵ뱤¸íº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 11:33~11:38 2-7. KGOG 3059 A cohort study to assess the safety and efficacy of PARP inhibitor maintenance after first-line therapy of Korean women with advanced ovarian/ fallopian/peritoneal cancer ±è¸í¼±(¼ººó¼¾Æ®º´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 11:38~11:43 2-8. KGOG 3067 Randomized Phase 2 trial of Cytoreductive Surgery for PARPi- Resistant Recurrent Ovarian Cancer Á¶Çö¿õ(°í´ë±¸·Îº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 11:43~11:48 2-9. JGOG3020 for early stage ovarian cancer Hiroshi Tanabe(JGOG )

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 11:48~11:58 3-1. An anticancer drug sensitivity test of patient-derived organoids as precision medicine for ovarian cancer patients À̵¿¿ì(MBD)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 11:58~12:08 Comparison of efficacy evaluation of vitamin E and vitamin C on taxol-induced neuropathy in ovarian cancer patients À̼±¹Ì(°í´ë¾È¾Ïº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 12:30~12:45 PRIMA: Niraparib in patients with newly diagnosed advanced ovarian cancer À̼ºÁ¾(¼­¿ï¼º¸ðº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 12:45~13:00 PRIME: Niraparib in Chines patients with newly diagnosed advanced ovarian cancer using ISD ÀÓ°¡¿ø(µ¿±¹´ëÀϻ꺴¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 13:00~13:15 NOVA: Niraparib in patients with recurrent ovarian cancer Àü¼·(¼øõÇâõ¾Èº´¿ø)

Åä·Ð 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 13:15~13:20 discussion ()

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 13:30~13:50 Digital application for PRO in cancer patients ³²º´È£(Ç층½º)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 13:50~14:10 Health-related quality of life assessment in medical oncology practice and adaptation of digital device in clinical practice ¹Ú¼¼ÈÆ(»ï¼º¼­¿ïº´¿ø)

Åä·Ð 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 14:10~14:15 discussion ()

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 15:00~15:30 NOW the Game has changed: NRG-GY018 Dr. Ramez Eskander(NRG Oncology)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 15:30~15:45 ECCC-CR ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 15:45~15:50 Review of ongoing study-KGOG 2015s À̹æÇö(ÀÎÇϴ뺴¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 15:50~15:55 Review of ongoing study-KGOG2020 ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 15:55~16:00 Review of ongoing study-KGOG2024 ÃÖ¹Îö(ºÐ´çÂ÷º´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 16:00~16:05 Review of ongoing study-KGOG2029 ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 16:05~16:10 Review of ongoing study-KGOG2030 ÀÌÁ¤À±(¼¼ºê¶õ½ºº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 16:10~16:15 Review of ongoing study-KGOG2034 ±èÀç¿ø(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 16:15~16:25 Characteristics, risk factors, and prognosis of incidentally diagnosed uterine neoplasm: a multiple institutional study ¹é¹ÎÇö(ÇѸ²´ë¼º½Éº´¿ø)

±âŸ 05¿ù 20ÀÏ ÄÁÆÛ·±½ºÈ¦ 16:25~16:27 closing ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2023 Spring Semi-Annual Meeting 2ÀÏÂ÷ : 2023-05-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѹ̼¼¼ö¼úÇÐȸ, ´ëÇѼöºÎ¿Ü°úÇÐȸ 2023 ÇÕµ¿ ½ÉÆ÷Áö¾ö : 2023-05-20
´ÙÀ½±Û ´ëÇÑÁ·ºÎÁ·°üÀýÇÐȸ - Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2023-05-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20620 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼­¿ï¾Æ»êº´¿ø ´ç´¢º´ °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-30 0 102 2024-04-30
20619 °æ³² »ï¼ºÃ¢¿øº´¿ø (¿Â¶óÀÎ)»ï¼ºÃ¢¿ø Ambulatory Pediatrics 2024 : 2024-06-29 0 81 2024-04-30
20618 °æºÏ Á¦8Â÷ ´ëÇѸðüžÆÀÇÇÐȸ °³¿øÀǸ¦ À§ÇÑ ¿¬¼ö°­ÁÂ(¿µ³²) : 2024-06-29 0 35 2024-04-30
20617 ¼­¿ï °Ç±¹´ëÇб³º´¿ø 2024 KUMC Precision Medicine Lung Cancer Conference : 2024-06-28 0 27 2024-04-30
20616 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ ÀûÇ÷±¸Áúȯ¿¬±¸ ½ÉÆ÷Áö¾ö : 2024-06-28 0 43 2024-04-30
20615 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-°³¿ø°¡¿¡¼­ ÀÇ·ÚÇÑ µÎ°æºÎ¾Ï ȯÀÚÀÇ Ä¡·á ¹× °æ°ú : 2024-06-27 0 32 2024-04-30
20614 ¼­¿ï 2024³â ´ëÇÑÈäºÎ¿µ»óÀÇÇÐȸ ¿¬¼ö°­Á : 2024-06-23 0 28 2024-04-30
20613 ´ë±¸ ´ëÇѽºÆ÷Ã÷ÀÇÇÐȸ Sports Medicine Symposium 2024 in Daegu : 2024-06-23 0 64 2024-04-29
20612 ¼­¿ï 2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦12Â÷ Clinical Densitometry Course : 2024-06-23 0 46 2024-04-29
20611 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(2ÀÏÂ÷) : 2024-06-22 0 51 2024-04-29
20610 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø (¿Â¶óÀÎ) 6¿ù 21ÀÏ ±Ý¿äÁý´ãȸ(ÀÌ°ü ÁúȯÀÇ Áø´Ü°ú Ä¡·á) : 2024-06-21 0 45 2024-04-29
20609 °æ±â ¾È»ê ¹× ½ÃÈ­Áö¿ª À̺ñÀÎÈÄ°ú Àǻ縦 À§ÇÑ Áý´ãȸ(¾È¸é¸¶ºñ) : 2024-06-21 0 35 2024-04-29
20608 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(1ÀÏÂ÷) : 2024-06-21 0 43 2024-04-29
20607 ¼­¿ï 2024 ´ëÇÑȯ°æõ½ÄÆóÁúȯÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-21 0 46 2024-04-29
20606 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-¿Ü·¡¿¡¼­ °£´ÜÇÏ°Ô ÇÒ ¼ö ÀÖ´Â À½¼ºÄ¡·á : 2024-06-20 0 30 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷